Compare Gilead Sciences, Inc. (GILD) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs LTC Properties Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while LTC Properties Inc trades at $43.29 (market cap $2.25B). The key difference: Gilead Sciences, Inc. is far larger — about 80.9× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.45%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and LTC Properties Inc for 89 Days on average.
| GILD | LTC | |
|---|---|---|
Market Cap | $182.09B | $2.25B |
Volume | 4,960,247 | 1,238,557 |
Sector | Health | Real Estate |
52-Week High | $155.80 | $43.50 |
52-Week Low | $116.74 | $33.98 |
Typical Hold Time | 111 Days | 89 Days |
Enterprise Value | $205.15B | $2.99B |
Dividend Yield | 2.23% | 5.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
LTC Properties trades at $41.81, down 1.48% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The REIT maintains strong profitability with 38.93% net margins and pays consistent monthly dividends of $0.19 per share. Recent acquisitions totaling $360 million accelerate the company's SHOP portfolio transformation, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with demographic tailwinds in senior housing but faces execution risks from aggressive expansion. The stock trades at reasonable valuations (P/E 14.93) with upside to analyst targets, though rising interest rates and integration challenges warrant caution for the growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
